Noscapine (Synonyms: 那可丁; (S,R)-Noscapine)

目录号: HY-13716 纯度: 98.70%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Noscapine ((S,R)-Noscapine) 是一种具有口服活性的苯酞异喹啉生物碱，具有强效镇咳作用。Noscapine 通过激活 sigma 阿片类受体 (sigma opioid receptors) 发挥镇咳作用，是一种非竞争性 Bradykinin 抑制剂。Noscapine 破坏微管动力学，诱导细胞有丝分裂停滞和凋亡 (apoptosis) 以及活性。Noscapine 具有抗癌，神经保护，抗炎活性，并且可以穿越血脑屏障。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Noscapine Chemical Structure

CAS No. : 128-62-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
100 mg	￥250	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Noscapine:

MCE 顾客使用本产品发表的 1 篇科研文献

•Patent. US20180263995A1.

Noscapine 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Opioid Receptor 亚型特异性产品:

查看所有亚型

μ Opioid Receptor/MOR κ Opioid Receptor/KOR δ Opioid Receptor/DOR NOP Receptor/ORL1

生物活性
纯度 & 产品资料
参考文献

生物活性

Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier^[1]^[2]^[3]^[4]^[5].

IC₅₀ & Target

Sigma opioid receptors^[4] Bradykinin^[5] Apoptosis^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	EC₅₀	25 μM Compound: 1, noscapine	Effect on cell growth in A549 cells by MTS assay Effect on cell growth in A549 cells by MTS assay	[PMID: 16279766]
A549	IC₅₀	62.9 μM Compound: 1	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 25453814]
A549	IC₅₀	65.2 μM Compound: Noscapine	Inhibition of NF-kappaB activation in human TNFalpha-stimulated A549 cells preincubated for 2 hrs before TNFalpha challenge measured after 7 hrs post stimulation by luciferase reporter gene assay Inhibition of NF-kappaB activation in human TNFalpha-stimulated A549 cells preincubated for 2 hrs before TNFalpha challenge measured after 7 hrs post stimulation by luciferase reporter gene assay	[PMID: 22137846]
Bel-7402	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
HEK293	IC₅₀	2.6 μM Compound: noscapine	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	34.5 μM Compound: noscapine	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HeLa	IC₅₀	24 μM Compound: 1	Antiproliferative activity against human HeLa cells after 72 hrs by MTS assay Antiproliferative activity against human HeLa cells after 72 hrs by MTS assay	[PMID: 25453814]
Hep 3B2	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
HepG2	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
Huh-7	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
MCF7	IC₅₀	18.8 μM Compound: 5	Antiproliferative activity against human MCF7 cells after 6 days by MTT assay Antiproliferative activity against human MCF7 cells after 6 days by MTT assay	[PMID: 30156410]
MCF7	IC₅₀	42.3 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 25453814]
MCF7	IC₅₀	57 μM Compound: Noscapine	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay	[PMID: 25240616]
MDA-MB-231	IC₅₀	64 μM Compound: Noscapine	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by methylene blue staining-based assay	[PMID: 25240616]
MHCC97H	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
NCI/ADR-RES	IC₅₀	17.4 μM Compound: 5	Antiproliferative activity against human NCI/ADR-RES cells after 6 days by MTT assay Antiproliferative activity against human NCI/ADR-RES cells after 6 days by MTT assay	[PMID: 30156410]
NCI-H460	IC₅₀	34.7 μM Compound: 6	Cytotoxicity against human H460 cells after 72 hrs Cytotoxicity against human H460 cells after 72 hrs	[PMID: 25811651]
PLC-PRF-5	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SH-SY5Y	IC₅₀	80.3 μM Compound: Noscapine	Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay	[PMID: 25728023]
SMMC-7721	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-182	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-387	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-398	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-423	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-449	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]
SNU-475	IC₅₀	> 1000 nM Compound: 1	Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay	[PMID: 22320354]

体外研究
(In Vitro)

Noscapine (0-1000 μM; 0-96 hours; rat C6 glioma cells) treatment inhibits cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner. Noscapine inhibits the viability of rat C6 glioma cells with an IC₅₀ of 250 μM at 72 hours^[1].
Noscapine exposure causes abnormal S-phase reentry, increases mitotic arrest and results in excessive DNA accumulation^[1].
Cylindromatosis increases the ability of noscapine to induce mitotic arrest and apoptosis. Cylindromatosis enhances the effect of noscapine on microtubule polymerization and promotes noscapine binding to microtubules^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Rat C6 glioma cells
Concentration:	0 μM, 0.1 μM, 1 μM, 2 μM, 10 μM, 50 μM, 100 μM, 1000 μM
Incubation Time:	0 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours
Result:	Inhibited cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner.

体内研究
(In Vivo)

Noscapine (300 mg/kg; oral gavage; daily; for 15 days; athymic female mice) treatment reduces tumor growth in mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic female mice (nu/nu) (8-week-old) injected with rat C6 glioma cells^[1]
Dosage:	300 mg/kg
Administration:	Oral gavage; daily; for 15 days
Result:	Revealed a significant reduction of tumor volume.

分子量

413.42

Formula

C₂₂H₂₃NO₇

CAS 号

128-62-1

性状

固体

颜色

White to off-white

中文名称

那可丁；诺斯卡品；那可汀；诺司卡宾

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 30 mg/mL (72.57 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4188 mL	12.0942 mL	24.1885 mL
5 mM	0.4838 mL	2.4188 mL	4.8377 mL
10 mM	0.2419 mL	1.2094 mL	2.4188 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.05 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.05 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 98.70%

选择批次：

Data Sheet (643 KB) SDS (392 KB)

COA (298 KB) LCMS (93 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Jaren W Landen, et al. Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth. Clin Cancer Res. 2004 Aug 1;10(15):5187-201. [Content Brief]

[2]. Yunfan Yang, et al. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics. 2015 Mar 2;5(7):656-66. [Content Brief]

[3]. Vartika Tomar, et al. Noscapine and Its Analogs as Chemotherapeutic Agent: Current Updates. Curr Top Med Chem. 2017;17(2):174-188. [Content Brief]

[4]. Bianca Lokhorst, et al. Interaction of OTC Drug Noscapine and Acenocoumarol and Phenprocoumon. Br J Clin Pharmacol. 2019 May;85(5):1041-1043. [Content Brief]

[5]. S A Ebrahimi, et al. Interaction of Noscapine With the Bradykinin Mediation of the Cough Response. Acta Physiol Hung. 2003;90(2):147-55. [Content Brief]

Noscapine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4188 mL	12.0942 mL	24.1885 mL	60.4712 mL
	5 mM	0.4838 mL	2.4188 mL	4.8377 mL	12.0942 mL
	10 mM	0.2419 mL	1.2094 mL	2.4188 mL	6.0471 mL
	15 mM	0.1613 mL	0.8063 mL	1.6126 mL	4.0314 mL
	20 mM	0.1209 mL	0.6047 mL	1.2094 mL	3.0236 mL
	25 mM	0.0968 mL	0.4838 mL	0.9675 mL	2.4188 mL
	30 mM	0.0806 mL	0.4031 mL	0.8063 mL	2.0157 mL
	40 mM	0.0605 mL	0.3024 mL	0.6047 mL	1.5118 mL
	50 mM	0.0484 mL	0.2419 mL	0.4838 mL	1.2094 mL
	60 mM	0.0403 mL	0.2016 mL	0.4031 mL	1.0079 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

Noscapine (Synonyms: 那可丁; (S,R)-Noscapine)

Customer Review

Other Forms of Noscapine:

MCE 顾客使用本产品发表的 1 篇科研文献

Noscapine 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Opioid Receptor 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Noscapine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Noscapine (Synonyms: 那可丁; (S,R)-Noscapine)

Customer Review

Other Forms of Noscapine:

Noscapine 相关抗体

MCE 顾客使用本产品发表的 1 篇科研文献

Noscapine 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Opioid Receptor 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Noscapine 相关抗体:

摩尔计算器

稀释计算器

Noscapine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z